STAT+: Faze Medicines, a biotech focused on neurological diseases, is shutting down
A biotech company that hoped to use cell biology to address neurological disorders is shutting down.
Faze Medicines was built by VC Third Rock Ventures and launched in 2020 with $81 million from Third Rock, Casdin Capital, and venture funds run by drug giants Novartis, Eli Lilly, and AbbVie.
